Search Results

You are looking at 1 - 10 of 237 items for :

  • anticoagulant x
Clear All
Open access

Georgi G. Zhelev, Kojcho P. Koev, Vladimir D. Dimitrov and Vladimir S. Petrov

disinfection, disinsection and deratization preparations authorized in the Republic of Bulgaria. In: Deratization preparations (pp. 181-189), Sofia: Videnov&son. 5. Hadlеr, M., Buckle, Al. (1992). Forty five years of anticoagulant rodenticides – past, present and future trends. Proceeding of the 15th Vertebrate Pest Conference. March, 3-5, (pp. 149-155), Hyatt Newporter, Newport Beach, California, USA. 6. Ishizuka, M., Tanikawa, Ts., Tanaka, K.D., Heewon, M., Okajiama, F., Sakamoto, K.Q., Fujita, Sh. (2008). Pesticide resistance in wild mammals-Mechanisms of

Open access

Dragana Lakic, Jovana Travica, Marina Odalovic and Ivana Tadic

.1302/0301-620X.90B2.20106. 8. Bass AR. (2015). Using new oral anticoagulants in patients undergoing major orthopedic surgery. Curr Rheumatol Rep. 17(4), 25. DOI: 10.1007/s11926-015-0498-z. 9. Eriksson BI, Quinlan DJ, Weitz JI. (2009). Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 48(1), 1-22. DOI: 10.2165/0003088-200948010-00001. 10. Wong PC, Crain EJ, Pinto DJ, Watson CA. (2007). Dose-Dependent Antithrombotic Effects of Apixaban, an Oral Direct Factor Xa Inhibitor, in

Open access

Hakima Belattar and S. Himour

essencial das folhas de Tropaeolum majus . SaBios-Revista de Saúde e Biologia . 2014 , 9 (2), 46-53. [5]. Kortchinsky, T.; Vigue, B.; Samama, C. M., Antagonisation des héparines et des nouveaux anticoagulants. Ann. Fr. Anesth. Reanim ., 2013 , 32 , 37-49. [6]. Li, Y.; Qian, Z. J.; Ryu, B.; Lee, S. H.; Kim, M. M.; Kim, S. K., Chemical components and its antioxidant properties in vitro: an edible marine brown alga, Ecklonia cava . Bioorg. Med. Chem., 2009 , 17 , 1963-1973. [7]. O’leary, K. A.; Pascual-Tereasa, S.; Needs, P. W.; Bao, Y. P.; O

Open access

Smaranda Arghirescu, Mihaela Bătăneanț, Cristian Jinca, Andreea Pașcalău, Mihaela Lelik, Mihaela Preja, Ladislau Ritli, E.C. Ursu, Margit Șerban and Hortensia Ioniță

References 1. Yoneyama A, Nakahara K. EDTA-dependent pseudothrombocytopenia- differentiation from true thrombocytopenia. Nihon Rinsho. 2003;61(4):569-74. 2. Schrezenmeier H, Müller H, Heimpel H, Seifried E. Anticoagulant-induced pseudothrombocytopenia and pseudoleucocytosis. Thromb Haemost. 1995;73(3):506-13. 3. Bizzaro N. EDTA-Dependent Pseudothrombocytopenia: A Clinical and Epidemiological Study of 112 Cases, With 10-Year Follow-Up. Am J Hematol. 1995

Open access

J. Stasko, J. Stasko, M. Janickova, K. Mikuskova, I. Malachovsky, P. Gengelova, M. Kasaj, M. Smatanova and D. Statelova

References 1. Schulman S. Advantages and limitations of the new anticoagulants. J Int Med 2014; 275(1): 1-11. 2. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. J Thromb Haemost. 2011;105(5):908-19. 3. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009

Open access

Katayoon Karimzadeh

antioxidant activity of polysaccharides from Rana chensinensis skin. Carbohydr Polym . 2015;115:25-31. 8. Yang J, Wanga Y, Jiang T, Lv Z. Novel branch patterns and anticoagulant activity of glycosaminoglycan from sea cucumber Apostichopus japonicus. Int JBiol Macromol. 2015;72:911-8. 9. Rajapakse N, Jung WK, Mendis E, Moon SH, Kim SK. A novel anticoagulant purified from fish protein hydrolysate inibitis factor XIIa and platelet aggregation. Life Science . 2005;76(22): 2607-19. 10. Krichen F, Karaoud W, Sila A, Abdelmalek BE, Ghorbel R, Ellouz

Open access

Silivastru (Cozlea) Ionela, Cozlea Daniel Laurentiu, Keresztesi Arthur Attila, Asofie Gabriela, Cozlea Laurentiu, Oltean Galafteon and Dobru Daniela

fibrillation patients: The Euro Heart Survey. Chest. 2010;138(5):1093-1100. 6. Thrift AG, Donnan GA, Mc Neil JJ. Epidemiology of intracranial hemorrhage. Epidemiologic Reviews. 1995;17:361-381. 7. Kase CS. Intracerebral hemorrhage. Baillière’s Clinical Neurology. 1995;4:247-278. 8. Shorr RL, Ray WA, Daugherty JR et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk of hemorrhagic peptic ulcer disease. Annals of Internal Medicine. 1993;153:1665-1670. 9. Eva Prescott, Rikke Sørensen

Open access

Leszek Czerchawski and Wojciech Witkiewicz

recombinant factor VIIa to reverse anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550--54. The van Gogh Investigators. Idraparinux versus Standard Therapy for Venous Thromboembolic Disease. 2007; 357: 1094--1104. Kapalan KL, Francis CW : Direct thrombin inhibitors. Semin Hemotol 2002; 39: 187--96. Lin H, Fleming NW, Moor PG : Anticoagulation for patients with heparin induced thrombocytopenia using recombinant hirudin during

Open access

Xiao-huan Gong, Jin-ming Yu, Yong Mao and Da-yi Hu

the treatment of NSTE-ACS is anticoagulants. The common anticoagulants are unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), whose clinical efficacy has been proved by many clinical trials. A new anticoagulant, fondaparinux, with satisfactory efficacy and safety, may play a crucial role in the treatment of ACS. [ 3 ] Based on the clinical data of 1,502 NSTE-ACS patients, the study aims to assess the anticoagulant therapy for NSTE-ACS in China, explore the severity of its two subtypes, reveal the problems in the treatment of NSTE-ACS, and offer

Open access

Maria-Magdalena Leon-Constantin, Alexandra Maștaleru, Ovidiu Mitu, Madalina Zota, Teodor Vasilcu, Radu Gavril and Florin Mitu

. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. 11. Siegal DM, Curnutte JT, Connolly SJ et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl JMed. 2015;373(25):2413-24. 12. Ansell JE, Bakhru SH, Laulicht BE et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141-2. 13. Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Idarucizumab, a specific reversal agent for dabigatran: mode of action